ExodusPoint Capital Management LP Purchases 58,165 Shares of Ascendis Pharma A/S $ASND

ExodusPoint Capital Management LP increased its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 235.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 82,888 shares of the biotechnology company’s stock after buying an additional 58,165 shares during the quarter. ExodusPoint Capital Management LP’s holdings in Ascendis Pharma A/S were worth $17,675,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of ASND. Advisory Services Network LLC bought a new position in shares of Ascendis Pharma A/S during the third quarter worth about $26,000. Arax Advisory Partners grew its holdings in shares of Ascendis Pharma A/S by 212.2% during the fourth quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock worth $33,000 after buying an additional 104 shares in the last quarter. Leonteq Securities AG bought a new position in shares of Ascendis Pharma A/S during the fourth quarter worth about $36,000. Jones Financial Companies Lllp grew its holdings in shares of Ascendis Pharma A/S by 57.2% during the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after buying an additional 83 shares in the last quarter. Finally, Global Retirement Partners LLC grew its holdings in shares of Ascendis Pharma A/S by 111.9% during the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock worth $46,000 after buying an additional 113 shares in the last quarter.

Ascendis Pharma A/S Stock Up 3.5%

ASND stock opened at $231.20 on Wednesday. Ascendis Pharma A/S has a twelve month low of $160.86 and a twelve month high of $250.74. The company has a market cap of $14.42 billion, a price-to-earnings ratio of 26.67 and a beta of 0.39. The business has a 50 day moving average price of $232.07 and a two-hundred day moving average price of $223.94. The company has a quick ratio of 0.72, a current ratio of 1.00 and a debt-to-equity ratio of 0.79.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.21 by $0.11. The business had revenue of $285.45 million during the quarter, compared to analyst estimates of $362.47 million. Analysts anticipate that Ascendis Pharma A/S will post 14.25 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently issued reports on ASND. Barclays increased their price objective on Ascendis Pharma A/S from $342.00 to $345.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Cantor Fitzgerald restated an “overweight” rating and issued a $300.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Jefferies Financial Group began coverage on Ascendis Pharma A/S in a research note on Monday, March 16th. They issued a “buy” rating and a $290.00 price target for the company. The Goldman Sachs Group restated a “buy” rating and issued a $255.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Finally, Wolfe Research restated an “outperform” rating and issued a $260.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Ascendis Pharma A/S currently has an average rating of “Buy” and an average target price of $295.39.

Insider Buying and Selling

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime bought 400 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were acquired at an average cost of $237.80 per share, with a total value of $95,120.00. Following the acquisition, the director owned 400 shares of the company’s stock, valued at $95,120. The trade was a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Flemming Steen Jensen sold 19,460 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $238.49, for a total value of $4,641,015.40. The disclosure for this sale is available in the SEC filing. 40.00% of the stock is currently owned by insiders.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark?based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long?acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once?weekly growth hormone therapy approved by the U.S.